Biocon Ltd

NSE: BIOCON · BSE: 532523 · Pharmaceuticals & Biotechnology · 10 announcements

Share price: ₹382.15
Market cap: ₹62,279 Cr
Revenue (annual): ₹16,927 Cr
Net profit (annual): ₹385.6 Cr
P/E (TTM): 125.7×Sector 50.4×
Promoter holding: 44.68%-0.23% QoQ
FII holding: 8.14%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 6 Financial Results 2 New Order Win 1 Business Update 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

1 announcement with these filters

21 Sep 2026 08:26 IST NSE

Business Update

Biocon Business Update

Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.

Read the filing ↗